Full-Time
Senior Network Engineer
Freenome
201-500 employees
Blood-based multiomics cancer detection tests
Compensation Overview
$156.8k - $200k/yr
Daly City, CA, USA
Hybrid
 IT & Security (2) |
|---|
| , |
- A minimum of 5 years Network Engineering experience.
- A minimum of 3 years Firewall security experience.
- A minimum of 3 years experience with configuring and managing Palo Alto Network firewalls.
- Juniper Networks JNCIP-ENT certification or equivalent experience.
- Advanced understanding of network hardware, software, protocols, and technologies.
- Experience with enterprise wireless network solutions and deployments.
- Hands-on experience with SSL and IPsec VPNs.
- Experience with network monitoring, management, and troubleshooting tools.
- Ability to work individually, as well as in a dynamic team environment.
- Strong communication and problem-solving skills.
- Ability to prioritize and manage multiple tasks and projects simultaneously.
- Strong documentation skills.
- Lead the architecture design and implementation of the network infrastructure; both on-prem and in Cloud.
- Lead Zero Trust implementation and maintenance.
- Work closely with engineering and laboratory teams to gather requirements, analyze, and propose infrastructure solutions.
- Contribute to the delivery of a global standard network infrastructure.
- Develop and maintain network documentation, including diagrams, policies, procedures, and best practices.
- Troubleshoot and remediate any events impacting the operations and availability of the global network infrastructure.
- Experience working in Clinical Diagnostics or Pharmaceutical Manufacturing.
- Expert experience with Juniper Networks products and solutions.
- Expert experience with Palo Alto Network Firewalls, Prisma, and Panorama.
- Experience with efficient IP SOLIDserver DDI.
- Engineering networks in Google Cloud Platform or other cloud providers.
Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$1.1B
Headquarters
San Francisco, California
Founded
2014
Simplify's Take
What believers are saying
- SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
- SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
- Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.
What critics are saying
- Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
- SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
- Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.
What makes Freenome unique
- Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
- Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
- Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Freenome who can refer or advise you
Benefits
Competitive market-based salaries
Annual bonus opportunities
Relocation packages
Medical, dental, & vision coverage
401k
Wellness programs
Equity
PTO
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -3%Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."
– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]
Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.
– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw
Freenome appoints Linh H. Le as chief financial officer.